Toumaz Technology Successfully Delivers Technology Platform for DIAdvisor Project

Toumaz HoldingsToumaz Holdings, the specialist niche investor in emerging technologies, announced that its wholly-owned subsidiary Toumaz Technology Limited ('Toumaz Technology') has successfully completed the timely delivery of the hardware, software and sensors that are being used to capture large-scale data in the first phase of DIAdvisor's clinical trial.

DIAdvisorTM is a large-scale integrating project (IP) aiming at the development of a prediction-based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes. DIAdvisor will allow patients to actively and accurately predict their short-term blood glucose outlook at any time by analysing data retrieved from glucose measurements, insulin delivery data and specific patient parameters. The key data, captured by non-intrusive body-worn wireless monitors including those based on Toumaz Technology's breakthrough Sensium™ platform, will be used to create physiological mathematical modelling, control and prediction algorithms. The resulting analysis and prediction information will be wirelessly transmitted to a healthcare provider advisory service, with recommended action and treatment advice presented to the patient via a handheld mobile device such as a Personal Digital Assistant (PDA).

The first year of the project oversaw the implementation of a large-scale data-acquisition clinical trial involving 90 patients across three sites in Europe; France, Italy and Czech Republic. As leaders of Workpackage 4, Toumaz Technology is responsible for the device platform development, including hardware, software and sensors and has ensured the successful and timely delivery of this device platform in the first year of the project.

The collaborative DIAdvisor project received a 7.1 million European Community Grant in April 2008 and the large-scale four year research and development project is being coordinated by Novo Nordisk A/S, a world leader in diabetes care. It will be delivered by a consortium of 13 medical, industrial and academic partners, including the European Division of the International Diabetes Federation.

The DIAdvisorTM project consortium recently held its second General Assembly (GA2), to review progress at end of the first year of the project. The GA2 meeting was hosted by consortium members Toumaz Technology at the Institute of Biomedical Engineering at Imperial College London.

Dr Alison Burdett, Director of Technology for Toumaz Technology commented: "The development of the DIAdvisorTM personal blood glucose predictor and treatment advisor has the potential to revolutionise the therapy of millions of diabetes sufferers in Europe and worldwide, minimising the occurrence of diabetic complications and reducing healthcare costs. The research and development carried out by all partners during the first year of the DIAdvisor programme brings this worthwhile goal one step closer."

Professor Christofer Toumazou, chairman of Toumaz Holdings, commented: "Our increasingly sedentary lifestyles and unhealthy dietary habits have led to the incidence of diabetes approaching epidemic proportions. Our Sensium™ technology is proving core in the deployment of a commercial solution to produce a successful personal continuous predictable monitor that will help transform the lives for diabetes sufferers. In addition, our collaborative and working relationships with leaders in the diabetes treatment market such as Novo Nordisk, will enable Toumaz Holdings to continue to build its presence in this expanding market."

Related news articles:

About Toumaz Technology
Toumaz Technology Limited is the leading provider of ultra-low power wireless infrastructure for body monitoring solutions. Toumaz's ultra low-power smart sensor interface and transceiver platform - the Sensium™ - enables non-intrusive, real-time wireless monitoring of multiple vital signs for a wide range of healthcare and lifestyle management applications.

Based on Toumaz's patented ultra-low power Advanced Mixed Signal (AMx) technology, the Sensium™ provides the enabling technology to connect the mobile individual to healthcare providers - simply, affordably and unobtrusively.

For healthcare professionals, this transforms the possibilities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible, personalised healthcare, as well as better therapeutic outcomes.

Most Popular Now

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Why the NHS is Seeking to Make Media Ser…

Opinion Article by Dean Moody, Healthcare Services Director, Airwave Healthcare. Tim Kelsey and Martha Lane Fox called for WiFi to be made available free of charge throughout the NHS back in...

An AI-Powered Pipeline for Personalized …

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

AI could Transform How Hospitals Produce…

A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

Great Start for Ideas and Innovations: D…

8 - 10 April 2025, Berlin, Germany. From 15 October to 15 November 2024, the DMEA invites experts from business, science, politics and practice to actively participate in shaping the congress...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...